Enanta Pharmaceuticals, Inc (ENTA) Dividend History

Company News

• Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight

  The urticaria pipeline is rapidly expanding, with over 20 leading companies developing 25+ new treatments to address the rising prevalence of the condition. Advances in biologic therapies and a strong R&D pipeline are driving progress, while improved healthcare infrastructure and digital innovations enhance patient access and outcomes.

  GlobeNewswire Inc.

  Featured Companies: CLDX KNSA REGN
• Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Tops Revenue Estimates

  Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -16.67% and 3.55%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

  Zacks Investment Research

  Featured Companies: PRPH
• Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Lags Revenue Estimates

  Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -33.90% and 20.83%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

  Zacks Investment Research

  Featured Companies: PROF
• Strength Seen in Enanta Pharmaceuticals (ENTA): Can Its 13.8% Jump Turn into More Strength?

  Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

  Zacks Investment Research

  Featured Companies: PTCT
• The Zacks Analyst Blog Highlights Enanta, OneConnect Financial, KNOT Offshore, Hippo Holdings and H World

  Enanta, OneConnect Financial, KNOT Offshore, Hippo Holdings and H World are included in this Analyst Blog.

  Zacks Investment Research

  Featured Companies: HIPO KNOP